San Diego-centered Viking Therapeutics marked by itself as a significant competitor during the weight loss drug current market in February following revealing promising facts from the mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when offered as a weekly injection and in March the